Pharmacy presentation about BCS classification its criteria.Biowaiever and its conditions .permeability studies in vivo,invitro,in situ.mpharmacy b pharmacy pharmaceutics
Bioavailability and bioequivalence studyMcpl Moshi
BCS is a scientific framework for classifying drug substances based on their aqueous solubility and intestinal permeability.
It is a drug development tool that allows estimation of solubility, dissolution and intestinal permeability affect that oral drug absorption.
Kashikar V S
PES Modern College of Pharmacy ( for ladies), Moshi Pune
Bioavailability and Bioequivalence studyMcpl Moshi
Bioavailability and Bioequivalence study, BCS is a scientific framework for classifying drug substances based on their aqueous solubility and intestinal permeability.
It is a drug development tool that allows estimation of solubility, dissolution and intestinal permeability affect that oral drug absorption.
A review on waiving in vivo bioequivalence tests or Biovaiwer, with a case review on the biowaiver monograph on Ibuprofen by H. POTTHAST, J.B. DRESSMAN, H.E. JUNGINGER, K.K. MIDHA, H. OESER, V.P. SHAH,
H. VOGELPOEL, D.M. BARENDS
in J Pharm Sci 94:2121–2131, 2005
Explaining different approaches to waive different BCS class medicines based on their solubility and permeability, as is described by FDA and WHO
Pharmacy presentation about BCS classification its criteria.Biowaiever and its conditions .permeability studies in vivo,invitro,in situ.mpharmacy b pharmacy pharmaceutics
Bioavailability and bioequivalence studyMcpl Moshi
BCS is a scientific framework for classifying drug substances based on their aqueous solubility and intestinal permeability.
It is a drug development tool that allows estimation of solubility, dissolution and intestinal permeability affect that oral drug absorption.
Kashikar V S
PES Modern College of Pharmacy ( for ladies), Moshi Pune
Bioavailability and Bioequivalence studyMcpl Moshi
Bioavailability and Bioequivalence study, BCS is a scientific framework for classifying drug substances based on their aqueous solubility and intestinal permeability.
It is a drug development tool that allows estimation of solubility, dissolution and intestinal permeability affect that oral drug absorption.
A review on waiving in vivo bioequivalence tests or Biovaiwer, with a case review on the biowaiver monograph on Ibuprofen by H. POTTHAST, J.B. DRESSMAN, H.E. JUNGINGER, K.K. MIDHA, H. OESER, V.P. SHAH,
H. VOGELPOEL, D.M. BARENDS
in J Pharm Sci 94:2121–2131, 2005
Explaining different approaches to waive different BCS class medicines based on their solubility and permeability, as is described by FDA and WHO
Biowaiver Based on BCS Classification System: Criteria and Requirements Accor...Tareq ✅
Bioavailability (BA)/bioequivalence (BE) parameters are generally required for approval of new and generic drugs. Bioequivalence based on plasma drug concentration has become the most frequently used and successful biomarker of safety and efficacy of a drug. According to the FDA’s regulations BA is defined as the rate and extent to which the active ingredient is absorbed from a drug product and becomes available at the site of action and BE can be defined as the absence of a significant difference in the rate and extent to which the active ingredient in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administrated at the same molar dose under similar conditions in a properly designed study. Two oral dosage forms are considered to be bioequivalent if both rate and extent of absorption are the same.
A Biowaiver means that in vivo bioavailability and/or bioequivalence studies may be waived (not considered necessary for product approval). Instead of conducting expensive and time consuming in vivo studies, a dissolution test could be adopted as the surrogate basis for the decision as to whether the two pharmaceutical products are equivalent.
The role of dissolution in the demonstration of bioequivalenceinemet
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
biopharmaceuticals classification system and biowaiverRavish Yadav
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
BCS Guideline for solubility and Dissolution.pptxImdad H. Mukeri
Briefly explanation of The Biopharmaceutics Classification System (BCS) of drug substance
and its solubility in the pH range of 1–7.5, absorption or intestinal membrane permeability
This slide outlines the evaluation methods of various Controlled Drug Delivery Systems (CDDS) used in the pharmaceutical industry. The controlled Drug Delivery Systems release the drug to the plasma at a controlled, pre-determined level to ensure prolonged and adequate drug supply for a longer time. The slide analyses the various evaluation methods, its pharmacokinetic properties and applications of the evaluation methods in various scenario.
Biowaiver Based on BCS Classification System: Criteria and Requirements Accor...Tareq ✅
Bioavailability (BA)/bioequivalence (BE) parameters are generally required for approval of new and generic drugs. Bioequivalence based on plasma drug concentration has become the most frequently used and successful biomarker of safety and efficacy of a drug. According to the FDA’s regulations BA is defined as the rate and extent to which the active ingredient is absorbed from a drug product and becomes available at the site of action and BE can be defined as the absence of a significant difference in the rate and extent to which the active ingredient in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administrated at the same molar dose under similar conditions in a properly designed study. Two oral dosage forms are considered to be bioequivalent if both rate and extent of absorption are the same.
A Biowaiver means that in vivo bioavailability and/or bioequivalence studies may be waived (not considered necessary for product approval). Instead of conducting expensive and time consuming in vivo studies, a dissolution test could be adopted as the surrogate basis for the decision as to whether the two pharmaceutical products are equivalent.
The role of dissolution in the demonstration of bioequivalenceinemet
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
biopharmaceuticals classification system and biowaiverRavish Yadav
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
BCS Guideline for solubility and Dissolution.pptxImdad H. Mukeri
Briefly explanation of The Biopharmaceutics Classification System (BCS) of drug substance
and its solubility in the pH range of 1–7.5, absorption or intestinal membrane permeability
This slide outlines the evaluation methods of various Controlled Drug Delivery Systems (CDDS) used in the pharmaceutical industry. The controlled Drug Delivery Systems release the drug to the plasma at a controlled, pre-determined level to ensure prolonged and adequate drug supply for a longer time. The slide analyses the various evaluation methods, its pharmacokinetic properties and applications of the evaluation methods in various scenario.
Similar to Biopharmaceutics Classification System-based Biowaivers & Comparison of Dissolution profile (20)
Overview on “Computer System Validation” CSVAnil Sharma
HI this is Anil Sharma, Executive Compliance in USV LTD. I want to share my brief knowledge on CSV with you. I hope my presentation will help you to understand basics of CSV.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
2. Table of Contents
1. Definitions
2. Introduction
3. Biopharmaceutics Classification System
4. Biopharmaceutics classification of the drug substance
5. Scope
6. Eligibility of a drug product for a BCS-based biowaiver
7. Acceptance Criteria for dissolution profile
8. Example
2 of 14
3. Definitions….
3 of 14
Bioavailability:
Bioavailability means the rate and extent to which the active drug ingredient is absorbed
from a drug product and becomes available at the site of drug action.
Bioequivalence:
Bioequivalence bioavailabilities (rate and extent of API absorption) of two drugs are
same after administration in the same dose.
In vivo:
It refers to a medical test, experiment, or procedure that is done on (or in) a living
organism, such as a laboratory animal or human.
4. Definitions….
4 of 14
In vitro:
It refers to a medical study or experiment that is done in the laboratory.
Narrow Therapeutic Index Drugs:
Drugs where small differences in dose or blood concentration may lead to serious
therapeutic failures and/or adverse drug reactions that are life-threatening.
Fixed-dose combination (FDC)
A medicine that combines two or more active drugs in a single dosage form such as
tablet or capsule.
5. Introduction
5 of 14
A bioequivalence study is basically a comparative study designed to establish
equivalence between test and reference products.
Two finished pharmaceutical products containing the same API are considered
bioequivalent if their bioavailabilities (rate and extent of API absorption) after
administration in the same dose lie within acceptable predefined limits.
Bioequivalence studies for solid oral dosage forms based on an approach termed the
Biopharmaceutics Classification System (BCS)
6. Biopharmaceutics Classification System
6 of 14
The BCS based biowaiver approach is intended to reduce the need for in vivo
bioequivalence studies i.e., it can provide a surrogate for in vivo bioequivalence.
In vivo bioequivalence studies may be exempted if an assumption of equivalence in in
vivo performance can be justified by satisfactory in vitro data.
The BCS is a scientific approach based on the aqueous solubility and intestinal
permeability characteristics of the drug substance(s).
The BCS categorizes drug substances into one of four BCS classes as follows:
Class I: high solubility, high permeability
Class II: low solubility, high permeability
Class III: high solubility, low permeability
Class IV: low solubility, low permeability
7. Biopharmaceutics classification of the drug substance
7 of 14
1. Solubility:
A drug substance is classified as highly soluble if the highest single therapeutic dose is
completely soluble in 250 ml or less of aqueous media over the pH range of 1.2–6.8 at 37±1°C.
Experimentally the solubility of the drug substance is determined over the pH range of 1.2–6.8
at 37±1ºC.
At least three pHs within this range, including buffers at pH 1.2, 4.5 and 6.8, should be
evaluated.
2. Permeability:
The assessment of permeability should preferentially be based on the extent of absorption
derived from human pharmacokinetic studies, e.g., absolute bioavailability.
High permeability can be concluded when the absolute bioavailability is ≥85%.
If high permeability is not demonstrated, the drug substance is considered to have low
permeability for BCS classification purposes.
8. Scope
8 of 14
1. BCS-based biowaivers may be used to demonstrate in vivo bioequivalence.
2. The BCS-based biowaiver is only applicable to immediate release, solid orally
administered dosage forms or suspensions designed to deliver drug to the systemic
circulation.
3. Drug products having a narrow therapeutic index are excluded from consideration
for a BCS-based biowaiver in this guidance.
4. Fixed-dose combination (FDC) products are eligible for a BCS-based biowaiver.
5. BCS-based biowaivers are applicable to drug products where the drug substance(s)
exhibit high solubility and, either high permeability (BCS Class I) or low
permeability (BCS Class III).
6. A biowaiver is applicable when the drug substance(s) in test and reference products
are identical.
9. Eligibility of a drug product for a BCS-based biowaiver
9 of 14
In vitro dissolution
Requirement for comparison of dissolution profile
1. Reference batch (Innovator Drug)
2. Test Batch
The test product should originate from a batch of at least 1/10 of production scale or 100,000
units, whichever is greater, unless otherwise justified.
3. Dissolution parameters and analytical method
Experiments should use compendial apparatus and suitably validated analytical method(s).
The following conditions should be employed in the comparative dissolution studies to
characterize the dissolution profile of the product:
Apparatus: paddle or basket
Volume of dissolution medium: 900 ml or
Temperature of the dissolution medium: 37±1°C.
Agitation: − paddle apparatus - 50 rpm, basket apparatus - 100 rpm.
10. Eligibility of a drug product for a BCS-based biowaiver
10 of 14
4. At least 12 units of reference and test product should be used for each dissolution profile
determination.
5. Three buffers: pH 1.2, pH 4.5, and pH 6.8. Pharmacopoeial buffers should be employed.
Additional investigation may be required at the pH of minimum solubility (if different from
the buffers above).
6. Organic solvents are not acceptable and no surfactants should be added.
7. Samples should be filtered during collection.
8. For gelatin capsules or tablets with gelatin coatings where cross-linking has been
demonstrated, the use of enzymes may be acceptable, if appropriately justified.
9. When high variability or coning is observed in the paddle apparatus at 50 rpm for both
reference and test products, the use of the basket apparatus at 100 rpm is recommended.
10. Additionally, alternative methods (e.g., the use of sinkers or other appropriately justified
approaches) may be considered to overcome issues such as coning & floating, if scientifically
proven.
11. Evaluation Method
11 of 14
For the comparison of dissolution profiles, where applicable, the difference &
similarity factor f2 should be estimated by using the following formula:
f1 = {[Σt=1n (Rt - Tt)]/[Σt=1n Rt] } x 100
f2 = 50 • log {[1 + (1/n)Σt=1n (Rt - Tt)2]-0.5 x 100}
In this equation f1 is difference factor and f2 is the similarity factor.
n is the number of time points.
R(t) is the mean % reference drug dissolved at time t
T(t) is the mean % test drug dissolved at time t
12. Acceptance Criteria for dissolution profile
12 of 14
The evaluation of the similarity factor is based on the following conditions:
1. A minimum of three time points (zero excluded).
2. The time points should be the same for test and reference products.
3. % RSD should not be more than 20% at early time-points (up to 10 minutes), and
should not be more than 10% at other time points.
4. F1 value should be close to 0 and generally f1 value up to 15 i.e. 0 to 15.
5. F2 value should be close to 100 and generally f2 value greater than 50 i.e. 50 to
100.